Alzheimer's disease, menopause and the impact of the estrogenic environment.

about

Effect of Estradiol on Neurotrophin Receptors in Basal Forebrain Cholinergic Neurons: Relevance for Alzheimer's Disease Neurotransmitter Pathway Genes in Cognitive Decline During Aging: Evidence for GNG4 and KCNQ2 Genes.

P2860

Q28071845-2D30B3AF-7925-46C0-B68B-42C023F1C877 Q47654383-C97FD60C-1397-465F-A55D-88F5F45F01EF

P2860

Alzheimer's disease, menopause and the impact of the estrogenic environment.

Item

http://www.wikidata.org/entity/Q38871979

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Alzheimer's disease, menopause and the impact of the estrogenic environment.

@en

type

Item

label

Alzheimer's disease, menopause and the impact of the estrogenic environment.

@en

prefLabel

Alzheimer's disease, menopause and the impact of the estrogenic environment.

@en

P1476

Alzheimer's disease, menopause and the impact of the estrogenic environment.

@en

P2093

A Pines

http://www.w3.org/2001/XMLSchema#string

P2860

Sex differences in cognitive impairment in Alzheimer's disease

Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study

Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies

Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial

Effects of Hormone Therapy on Brain Volumes Changes of Postmenopausal Women Revealed by Optimally-Discriminative Voxel-Based Morphometry.

Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype

Cognitive changes after menopause: influence of estrogen

Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years.

Minireview: effects of different HT formulations on cognition.

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.

P304

430-432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13697137.2016.1201319

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27327261

http://www.w3.org/2001/XMLSchema#string

Alzheimer's disease, menopause and the impact of the estrogenic environment.

about

P2860

P2860

Alzheimer's disease, menopause and the impact of the estrogenic environment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698